Institute of Cellular Medicine

Staff Profile

Dr Rachel Crossland

Research Associate



2011: PhD Molecular Biology of Cancer, Newcastle University

2006: BSc Biomedical Sciences, Newcastle University (First class)



NanoString RNA:Protein competition awardee. May 2016.

EMEA Affymetrix Tumour Profiling competition awardee. April 2016.

British Council Researcher Links Scholarship - Extracellular Vesicles Workshop, Russia. Feb 2015.

Life Technologies Ion Torrent™ Transcriptome Profiling competition awardee. Jan 2015.

NanoString PanCancer Panel Driver Genes and Cancer Pathways competition awardee. April 2014.

NEPAC Travel Scholarship - American Society of Haematology 56th Annual Meeting. Dec 2014.

BACR non-student Travel Award - 12th International Conference on Malignant Lymphomas. June 2013.

First Poster Prize, Euroscicon Meeting - Biomarker Discovery: Driving Technologies. Feb 2013.

BSH Travel Scholarship - ESH International Conference on Lymphomas. Oct 2012.

ESH Scholarship - ESH International Conference on Lymphomas. Oct 2012.

Newcastle University Graduate School Award - North East Postgraduate Conference 2009.

ESH Scholarship - Biomarkers and Prognosis in Malignant Lymphoma ESH-EHA Scientific Workshop. Apr 2008.


Reviewer for the Newcastle Academic Health Partners Bioresource

Committee member of RealICM (Researchers Altogether ICM), Newcastle University

Topic Editor Frontiers Special Edition: Cell to Cell Communication by Extracellular Vesicles


British Association for Cancer Research

European Association for Cancer Research

British Society for Haematology

Pathological Society

Biochemical Society

UK Extracellular Vesicle Network



I am interested in the role of microRNAs as biomarkers and drivers in haematological malignancies and their complications, including graft versus host disease (GvHD).
I currently focus on aggressive B-cell non-Hodgkin lymphoma (B-NHL), specifically sporadic Burkitt lymphoma and diffuse large B-cell lymphoma. I am interested in further understanding the biology of relapse in lymphoma, in order to improve the outcome of relapsed/refractory disease. This approach involves comprehensive genomic profiling, including copy number analysis (CytoScan/OncoScan), targeted sequencing (HaloPlex), digital profiling of gene expression (NanoString) and transcriptome sequencing (AmpliSeq) in relation to disease biology and outcome. Further studies aim to address whether microRNAs may be useful biological indicators for disease outcome in B-NHL, particularly when assessed from clinically translational FFPE material.
I am also interested in the expression and function of microRNAs and their targets in GvHD, a complication of bone marrow transplants in which T cells in the donor bone marrow graft go on the offensive and attack the host's tissues. I am currently investigating if circulating microRNAs within the body fluids of GvHD patients (including microRNAs packaged within extracellular vesicles) are involved in disease patho-physiology and if so, whether they can be used to predict the incidence and severity of disease.



BSc: 4 undergraduate students between 2008-2015

MRes: 4 masters students between 2009-2015

PhD: Co-supervised 2 PhD students between 2013-2015

Clinical: 4th year elective medical student project

Teaching course components as part of the Celleurope Initial Training Network: Immunohistochemistry Workshop and Molecular Biology Workshop.

Mentor to secondment Fellows from the Marie Curie Celleurope Initial Training Network: